Haploidentical Transplantation Effective as Front-line Therapy for Standard-risk ALL

Share this content:
HID transplantation might be an alternative front-line choice for standard-risk adults with acute lymphoblastic leukemia in first complete remission.
HID transplantation might be an alternative front-line choice for standard-risk adults with acute lymphoblastic leukemia in first complete remission.

Haploidentical donor (HID) transplants may be therapeutically equivalent to human leucocyte antigen (HLA)-matched sibling donor (MSD) and HLA-matched unrelated donor (MUD) transplants in standard-risk patients with acute lymphoblastic leukemia (ALL) in first complete remission (CR1), according to a study published in the British Journal of Haematology.1

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is recommended for high-risk adult patients with ALL in CR1, and evidence from previous studies suggests that patients with standard-risk ALL in CR1 could benefit from receiving HID, MSD, or MUD.

This study retrospectively assessed 348 standard-risk patients with ALL in CR1, of which 127 patients received HID, 144 received MSD, and 77 received MUD. Patients received prophylactic treatment for infection and graft-vs-host disease (GVHD).

There were no significant differences in the HID, MSD, and MUD arms in the 5-year cumulative overall survival (OS) rates (70.1%, 73.7%, and 69.8%, respectively; P = .525), the 5-year cumulative transplant related mortality (16.4%, 11.6%, and 19.6%, respectively; P = .162), and 5-year disease-free survival (68.7%, 67.3%, and 63.7%, respectively; P = .606) respectively.

No significant differences were observed in the HID, MSD, and MUD arms for grade 3 to 4 acute GVHD (aGVHD) (11.4%, 7.7%, and 13.5%, respectively; P = .468), 5-year relapse rate post-transplantation (14.8%, 21.1%, and 16.7%, respectively; P = .231), and 3-year GVHD relapse-free survival (50.8%, 54.9%, and 52.2%, respectively; P = .847) respectively.

The only significant difference among the HID, MSD, and MUD groups was observed in the cumulative incidence of grade 2 to 4 aGVHD (39.5%, 24.0%, and 40.3%, respectively; P = .020) respectively.

RELATED: Gilteritinib Granted Orphan Drug Status for Acute Myeloid Leukemia

The authors concluded that these “results suggest the outcomes of HID transplant are equivalent to those of MSD and MUD transplants. HID transplantation might be an alternative front-line choice for standard-risk adults with ALL in CR1 who lack a matched donor.”

Reference

  1. Han LJ, Wang Y, Fan ZP, et al. Haploidentical transplantation compared with matched sibling and unrelated donor transplantation for adults with standard-risk acute lymphoblastic leukaemia in first complete remission. Br J Haematol. 2017 Jul 24. doi: 10.111/bjh.14854 [Epub ahead of print]  

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters